1
|
Santarelli IM, Manzella DJ, Gallo Vaulet ML, Rodríguez Fermepín M, Crespo Y, Toledo Monaca S, Dobarro M, Fernández SI. Cycle threshold predicted mortality in a cohort of patients with hematologic malignancies infected with SARS-CoV-2. Rev Argent Microbiol 2023; 55:246-250. [PMID: 37208258 PMCID: PMC10130324 DOI: 10.1016/j.ram.2023.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Revised: 02/13/2023] [Accepted: 03/30/2023] [Indexed: 05/21/2023] Open
Abstract
When a SARS-CoV-2 RT-qPCR test is performed, it may determine an indirect measure of viral load called cycle threshold (Ct). Respiratory samples with Ct <25.0 cycles are considered to contain a high viral load. We aimed to determine whether SARS-CoV-2 Ct at diagnosis could predict mortality in patients with hematologic malignancies (lymphomas, leukemias, multiple myeloma) who contracted COVID-19. We included 35 adults with COVID-19 confirmed by RT-qPCR performed at diagnosis. We evaluated mortality due to COVID-19 rather than mortality due to the hematologic neoplasm or all-cause mortality. Twenty-seven (27) patients survived and 8 died. The global mean Ct was 22.8 cycles with a median of 21.7. Among the survivors, the mean Ct was 24.2, and the median Ct value was 22.9 cycles. In the deceased patients, the mean Ct was 18.0 and the median Ct value was 17.0 cycles. Using the Wilcoxon Rank Sum test, we found a significant difference (p=0.035). SARS-CoV-2 Ct measured in nasal swabs obtained at diagnosis from patients with hematologic malignancies may be used to predict mortality.
Collapse
Affiliation(s)
- Ignacio Martín Santarelli
- Universidad de Buenos Aires, Hospital de Clínicas "José de San Martín", Departamento de Medicina, Buenos Aires, Argentina; Universidad de Buenos Aires, Facultad de Medicina, Buenos Aires, Argentina.
| | | | - María Lucía Gallo Vaulet
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Microbiología Clínica, Inmunología y Virología Clínica, Buenos Aires, Argentina; Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina
| | - Marcelo Rodríguez Fermepín
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Microbiología Clínica, Inmunología y Virología Clínica, Buenos Aires, Argentina; Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina
| | | | | | - Martín Dobarro
- Sanatorio Sagrado Corazón, Buenos Aires, Argentina; Universidad de Buenos Aires, Hospital de Clínicas "José de San Martín, Departamento de Medicina, Programa de Hospital de Día, Buenos Aires, Argentina
| | - Sofía Isabel Fernández
- Universidad de Buenos Aires, Hospital de Clínicas "José de San Martín", Departamento de Medicina, Buenos Aires, Argentina; Universidad de Buenos Aires, Facultad de Medicina, Buenos Aires, Argentina
| |
Collapse
|
3
|
Lopardo G, Belloso WH, Nannini E, Colonna M, Sanguineti S, Zylberman V, Muñoz L, Dobarro M, Lebersztein G, Farina J, Vidiella G, Bertetti A, Crudo F, Alzogaray MF, Barcelona L, Teijeiro R, Lambert S, Scublinsky D, Iacono M, Stanek V, Solari R, Cruz P, Casas MM, Abusamra L, Luciardi HL, Cremona A, Caruso D, de Miguel B, Lloret SP, Millán S, Kilstein Y, Pereiro A, Sued O, Cahn P, Spatz L, Goldbaum F. RBD-specific polyclonal F(ab´) 2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial. EClinicalMedicine 2021; 34:100843. [PMID: 33870149 PMCID: PMC8037439 DOI: 10.1016/j.eclinm.2021.100843] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Revised: 03/10/2021] [Accepted: 03/17/2021] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND passive immunotherapy is a therapeutic alternative for patients with COVID-19. Equine polyclonal antibodies (EpAbs) could represent a source of scalable neutralizing antibodies against SARS-CoV-2. METHODS we conducted a double-blind, randomized, placebo-controlled trial to assess efficacy and safety of EpAbs (INM005) in hospitalized adult patients with moderate and severe COVID-19 pneumonia in 19 hospitals of Argentina. Primary endpoint was improvement in at least two categories in WHO ordinal clinical scale at day 28 or hospital discharge (ClinicalTrials.gov number NCT04494984). FINDINGS between August 1st and October 26th, 2020, a total of 245 patients were enrolled. Enrolled patients were assigned to receive two blinded doses of INM005 (n = 118) or placebo (n = 123). Median age was 54 years old, 65•1% were male and 61% had moderate disease at baseline. Median time from symptoms onset to study treatment was 6 days (interquartile range 5 to 8). No statistically significant difference was noted between study groups on primary endpoint (risk difference [95% IC]: 5•28% [-3•95; 14•50]; p = 0•15). Rate of improvement in at least two categories was statistically significantly higher for INM005 at days 14 and 21 of follow-up. Time to improvement in two ordinal categories or hospital discharge was 14•2 (± 0•7) days in the INM005 group and 16•3 (± 0•7) days in the placebo group, hazard ratio 1•31 (95% CI 1•0 to 1•74). Subgroup analyses showed a beneficial effect of INM005 over severe patients and in those with negative baseline antibodies. Overall mortality was 6•9% the INM005 group and 11•4% in the placebo group (risk difference [95% IC]: 0•57 [0•24 to 1•37]). Adverse events of special interest were mild or moderate; no anaphylaxis was reported. INTERPRETATION Albeit not having reached the primary endpoint, we found clinical improvement of hospitalized patients with SARS-CoV-2 pneumonia, particularly those with severe disease.
Collapse
Affiliation(s)
- Gustavo Lopardo
- Hospital Municipal Dr. Bernardo Houssay, Pte Hipólito Yrigoyen 1757, Florida, Provincia de Buenos Aires, Argentina
- Fundación del Centro de Estudios Infectológicos (FUNCEI), French 3085, Ciudad Autónoma de Buenos Aires, Buenos Aires C1425, Argentina
| | - Waldo H. Belloso
- Department of Research, Hospital Italiano de Buenos Aires. Pres. Tte. Gral. Juan Domingo Perón 4190, Ciudad Autónoma de Buenos Aires, Buenos Aires C1199, Argentina
| | - Esteban Nannini
- Departamento de Enfermedades Infecciosas, Sanatorio Británico, Paraguay 40, Rosario, Santa Fé S2000 CVB, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
| | - Mariana Colonna
- Inmunova S.A., 25 de mayo 1021, Villa Lynch, Gral. San Martín, Buenos Aires CP B1650HMP, Argentina
| | - Santiago Sanguineti
- Inmunova S.A., 25 de mayo 1021, Villa Lynch, Gral. San Martín, Buenos Aires CP B1650HMP, Argentina
| | - Vanesa Zylberman
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
- Inmunova S.A., 25 de mayo 1021, Villa Lynch, Gral. San Martín, Buenos Aires CP B1650HMP, Argentina
| | - Luciana Muñoz
- Inmunova S.A., 25 de mayo 1021, Villa Lynch, Gral. San Martín, Buenos Aires CP B1650HMP, Argentina
| | - Martín Dobarro
- Sanatorio Sagrado Corazón (OSECAC), Bartolomé Mitre 1955, Ciudad Autónoma de Buenos Aires, Buenos Aires CP1039, Argentina
| | - Gabriel Lebersztein
- Sanatorio Sagrado Corazón (OSECAC), Bartolomé Mitre 1955, Ciudad Autónoma de Buenos Aires, Buenos Aires CP1039, Argentina
| | - Javier Farina
- Hospital de Alta Complejidad Cuenca Alta S.A.M.I.C. Dr. Néstor Carlos Kirchner, RP6, Cañuelas, Provincia de Buenos Aires, Argentina
| | - Gabriela Vidiella
- Sanatorio Agote. Dr. Luis Agote 2477, Ciudad Autónoma de Buenos Aires, Buenos Aires C1425 EOE, Argentina
| | - Anselmo Bertetti
- Sanatorio Güemes, Francisco Acuña de Figueroa 1240, Ciudad Autónoma de Buenos Aires, Buenos Aires C1180, Argentina
| | - Favio Crudo
- Hospital Municipal Emilio Zerboni, Moreno 90, San Antonio de Areco, Provincia de Buenos Aires B2760, Argentina
- Universidad Nacional de San Antonio de Areco, Av. Güiraldes 689, San Antonio de Areco, Provincia de Buenos Aires, Argentina
| | | | - Laura Barcelona
- Hospital Municipal Dr. Bernardo Houssay, Pte Hipólito Yrigoyen 1757, Florida, Provincia de Buenos Aires, Argentina
| | - Ricardo Teijeiro
- Hospital General de Agudos Dr. Ignacio Pirovano, Av. Monroe 3555, Ciudad Autónoma de Buenos Aires, Buenos Aires C1428, Argentina
| | - Sandra Lambert
- Hospital de Alta Complejidad El Cruce Néstor Kirchner, Av. Calchaquí 5401, Florencio Varela, Provincia de Buenos Aires, Argentina
| | - Darío Scublinsky
- Clínica Zabala. Av. Cabildo 1295, Ciudad Autónoma de Buenos Aires, Buenos Aires C1426 AAM, Argentina
| | - Marisa Iacono
- Hospital Provincial Neuquén Dr. Castro Rendón, Buenos Aires 450, Neuquén Q8300, Argentina
| | - Vanina Stanek
- Sección de Infectología, Servicio de Medicina Interna, Hospital Italiano de Buenos Aires. Pres. Tte. Gral. Juan Domingo Perón 4190, Ciudad Autónoma de Buenos Aires, Buenos Aires C1199, Argentina
| | - Rubén Solari
- Hospital de Infecciosas Francisco Javier Muñiz, Uspallata 2272, Ciudad Autónoma de Buenos Aires, Buenos Aires C1282, Argentina
| | - Pablo Cruz
- Centro Gallego de Buenos Aires, Av. Belgrano 2199, Ciudad Autónoma de Buenos Aires, Buenos Aires C1096, Argentina
| | - Marcelo Martín Casas
- Clínica Adventista Belgrano. Estomba 1710, Ciudad Autónoma de Buenos Aires, Buenos Aires C1430 EGF, Argentina
| | - Lorena Abusamra
- Hospital Municipal Dr. Diego Thompson, Avellaneda 33, Villa Lynch, Gral. San Martín, Buenos Aires B1650, Argentina
| | - Héctor Lucas Luciardi
- Hospital Centro de Salud Zenón J. Santillán, Av. Avellaneda 750, San Miguel de Tucumán, Tucumán T4000, Argentina
| | - Alberto Cremona
- Hospital Italiano La Plata, Av. 51, La Plata, Provincia de Buenos Aires B1900, Argentina
| | - Diego Caruso
- Hospital Español, Av. Belgrano 2975, Ciudad Autónoma de Buenos Aires, Buenos Aires C1209, Argentina
| | | | - Santiago Perez Lloret
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
- Departamento de Docencia e Investigación, Facultad de Ciencias Médicas, Universidad Católica Argentina, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
- Universidad Abierta Interamericana, Centro de Altos Estudios en Ciencias Humanas y de la Salud (UAI-CAECIHS), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Av. San Juan 951, Ciudad Autónoma de Buenos Aires, Buenos Aires C1147 AAH, Argentina
| | - Susana Millán
- mAbxience, Manuel Pombo Angulo 28, 3rd floor, Madrid 28050, Spain
| | - Yael Kilstein
- PHV LATAM, AES, Amenábar 3851, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - Ana Pereiro
- Fundación Mundo Sano, Paraguay 1535, Ciudad Autónoma de Buenos Aires, Buenos Aires C1061ABC, Argentina
| | - Omar Sued
- Fundación Huésped, Pasaje Ángel Peluffo 3932PB, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - Pedro Cahn
- Fundación Huésped, Pasaje Ángel Peluffo 3932PB, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - Linus Spatz
- Inmunova S.A., 25 de mayo 1021, Villa Lynch, Gral. San Martín, Buenos Aires CP B1650HMP, Argentina
| | - Fernando Goldbaum
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
- Inmunova S.A., 25 de mayo 1021, Villa Lynch, Gral. San Martín, Buenos Aires CP B1650HMP, Argentina
- Fundación Instituto Leloir, IIBBA-CONICET. Av. Patricias Argentinas 435, Buenos Aires C1405BWE, Argentina
- CRIP - Centro de Rediseño e Ingeniería de Proteínas UNSAM Campus Miguelete. 25 de Mayo y Francia Villa Lynch, Gral. San Martín, Buenos Aires B1650HMK, Argentina
- Corresponding author at: Inmunova S.A., 25 de mayo 1021, Villa Lynch, Gral. San Martín, Buenos Aires CP B1650HMP, Argentina.
| | | |
Collapse
|
4
|
Briones A, Gagno S, Martisova E, Dobarro M, Aisa B, Solas M, Tordera R, Ramírez M. Stress-induced anhedonia is associated with an increase in Alzheimer's disease-related markers. Br J Pharmacol 2012; 165:897-907. [PMID: 21797840 DOI: 10.1111/j.1476-5381.2011.01602.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND AND PURPOSE Stress is believed to be associated with the development of neuropsychiatric disorders, including Alzheimer's disease (AD). We have studied mechanisms implicated in vulnerability to stress and the relationship with changes in AD-related markers. EXPERIMENTAL APPROACH Anhedonia induced by a chronic mild stress (CMS) procedure, applied for 6 weeks, was used to select rats vulnerable or resistant to stress. Sucrose intake, the Porsolt forced swimming test and cognitive deficits in the novel object recognition test (NORT) were used to characterize vulnerable and resilient rats. The antidepressant venlafaxine (20 mg·kg(-1) p.o.) or saline was administered daily during the last 2 weeks of CMS. Biochemical markers affected by stress, PKB, ERK and synaptophysin, and those associated with AD, amyloid β-protein (Aβ), β-secretase (BACE1) and τ phosphorylation, were measured in the hippocampus. KEY RESULTS After CMS, 40% of rats were resistant to the development of anhedonia (CMS-resistant to stress), whereas the remaining were responsive [CMS-anhedonic (CMSA)]. Only CMSA rats displayed significant increases in immobility time in the forced swimming test and cognitive deficits in the NORT, and significant decreases in synaptophysin, phosphorylated PKB and phosphorylated ERK1/2 expression in the hippocampus. Increased levels of Aβ40, BACE1 and τ phosphorylation were also found only in CMSA rats. All these effects in CMSA rats were reverted by treatment with venlafaxine. CONCLUSIONS AND IMPLICATIONS Vulnerability to stress might constitute a risk factor for the development of AD, and pharmacological treatment with venlafaxine may represent a therapeutic strategy for the treatment of stress-related disorders, including AD.
Collapse
Affiliation(s)
- A Briones
- Dpto Farmacologia, Universidad de Navarra, Pamplona, Spain
| | | | | | | | | | | | | | | |
Collapse
|